secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0000950170-24-106611
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio partners with Novo Nordisk for up to $530M in RNA editing deal for cardiometabolic targets
--------------------------------------------------------------------------------

- Up to $530M in upfront, development, and commercial milestone payments plus tiered royalties and R&D funding.
- Upfront fee of $10M for first target; potential additional upfront for second target if nominated.
- Korro grants exclusive worldwide license to Novo Nordisk for two undisclosed cardiometabolic targets using OPERA platform.
- Korro responsible for preclinical development; Novo Nordisk may advance programs through clinical studies.
- Deal allows Korro to retain internal pipeline focus while expanding RNA editing to high-prevalence diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024106611/0000950170-24-106611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024106611/krro-20240913.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer